{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:04:09Z","timestamp":1762297449309},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.vaccine.2009.05.003","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T05:02:18Z","timestamp":1243486938000},"page":"B30-B41","source":"Crossref","is-referenced-by-count":57,"special_numbering":"S2","title":["Quadrivalent meningococcal conjugate vaccines"],"prefix":"10.1016","volume":"27","author":[{"given":"David","family":"Pace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy E.","family":"Messonier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.05.003_bib1","unstructured":"Food and Drug Administration. Product approval information-licensing action, package insert: meningococcal (groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine Menactra\u00ae. Sanofi Pasteur. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2005. Available at http:\/\/www.fda.gov\/cber\/label\/menactralb.pdf."},{"key":"10.1016\/j.vaccine.2009.05.003_bib2","unstructured":"National Advisory Committee on Immunization (NACI). An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep. 2009;35(ACS-3):1\u201340."},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.003_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/10408418109085081","article-title":"Meningococci","volume":"8","author":"Sippel","year":"1981","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2009.05.003_bib4","series-title":"Vaccines","first-page":"399","article-title":"Meningococcal vaccines","author":"Granoff","year":"2008"},{"issue":"10","key":"10.1016\/j.vaccine.2009.05.003_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","article-title":"Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents","volume":"159","author":"Keyserling","year":"2005","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2009.05.003_bib6","unstructured":"Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-7):1\u201321."},{"issue":"1","key":"10.1016\/j.vaccine.2009.05.003_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide\u2013diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib8","unstructured":"Centers for Disease Control and Prevention. Report from the Advisory Committee on Immunization Practices (ACIP): decision not to recommend routine vaccination of all children aged 2\u201310 years with quadrivalent meningococcal conjugate vaccine (MCV4). MMWR 2008;57(17):462\u20135."},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.003_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.inf.0000126297.28952.f8","article-title":"Dose escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants","volume":"23","author":"Rennels","year":"2004","journal-title":"Ped Infect Dis J"},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.003_bib10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/infdis\/140.5.690","article-title":"Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children","volume":"140","author":"Gold","year":"1979","journal-title":"J Infect Dis"},{"issue":"8447","key":"10.1016\/j.vaccine.2009.05.003_bib11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0140-6736(85)90224-7","article-title":"Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine","volume":"2","author":"Reingold","year":"1985","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2009.05.003_bib12","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/infdis\/169.4.847","article-title":"Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel","volume":"169","author":"Zangwill","year":"1994","journal-title":"J Infect Dis"},{"issue":"34","key":"10.1016\/j.vaccine.2009.05.003_bib13","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1016\/j.vaccine.2005.03.031","article-title":"Immunogenicity of an investigational quadrivalent Neisseria meningitidis diphtheria toxoid conjugate vaccine in 2-year old children","volume":"23","author":"Granoff","year":"2005","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2009.05.003_bib14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.inf.0000243215.46312.4a","article-title":"Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine","volume":"25","author":"Pichichero","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib15","unstructured":"Onchee Y, Jackson L for the Vaccine Safety. Datalink Investigators. Risk of medically attended local reactions following Td, Tdap and Menactra vaccines in adolescents and young adults. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/Infectious Diseases Society of America (IDSA) 46th Annual meeting. Washington, DC, USA, October 25\u201328, 2008."},{"key":"10.1016\/j.vaccine.2009.05.003_bib16","unstructured":"Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee, September 22, 2004: briefing information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2004. Available at http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/04\/briefing\/2004-4072b1.htm."},{"issue":"4","key":"10.1016\/j.vaccine.2009.05.003_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","volume":"23","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib18","unstructured":"Centers for Disease Control and Prevention (CDC). Syncope after vaccination\u2014United States, January 2005\u2013July 2007. MMWR 2008;57(17):457\u201360."},{"issue":"1","key":"10.1016\/j.vaccine.2009.05.003_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2009.05.003_bib20","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.003_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2009.05.003_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":"Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants","volume":"28","author":"Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib23","series-title":"5th World Congress of the World Society for Pediatric Infectious Diseases (WSPID)","article-title":"Safety and immunogenicity of Novartis Vaccines, MenACWY conjugate vaccine after one or two doses administered to infants and young children","author":"Halperin","year":"2007"},{"key":"10.1016\/j.vaccine.2009.05.003_bib24","series-title":"23rd Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID)","article-title":"Immune response and immunological memory induced by a novel meningococcal ACWY-CRM conjugate vaccine (MenACWY) in toddlers","author":"Vesikari","year":"2005"},{"key":"10.1016\/j.vaccine.2009.05.003_bib25","series-title":"26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"MenACWY-CRM, a novel quadrivalent meningococcal conjugate vaccine, is well tolerated and immunogenic in infancy through adolescence","author":"Black","year":"2008"},{"issue":"9431","key":"10.1016\/j.vaccine.2009.05.003_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(04)16725-1","article-title":"Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction","volume":"364","author":"Trotter","year":"2004","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2009.05.003_bib27","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/344324","article-title":"Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom","volume":"186","author":"Borrow","year":"2002","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.003_bib28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":"A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib29","series-title":"Pediatric Academic Societies (PAS) Annual Meeting","article-title":"A phase III study comparing the safety and immunogenicity of a novel quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, with the licensed MCV4, Menactra, in adolescents","author":"Jackson","year":"2008"},{"issue":"2","key":"10.1016\/j.vaccine.2009.05.003_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide\u2013protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib31","series-title":"45th Annual meeting of the Infectious Diseases Society of America (IDSA)","article-title":"Safety and immunogenicity 12 months post-vaccination with Novartis Vaccines\u2019 tetravalent glycoconjugate meningococcal ACWY vaccine in children aged 2\u201310 years","author":"Black","year":"2007"},{"issue":"7659","key":"10.1016\/j.vaccine.2009.05.003_bib32","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2009.05.003_bib33","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2009.05.003_bib34","doi-asserted-by":"crossref","first-page":"A63","DOI":"10.1016\/j.vaccine.2007.04.043","article-title":"Issues surrounding standardization of meningococcal group W135 serology","volume":"25","author":"Balmer","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.05.003_bib35","series-title":"26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID)","article-title":"Immunogenicity and safety of MenACWY-CRM, a novel quadrivalent meningococcal conjugate vaccine, administered concomitantly with Tdap in healthy subjects 11\u201325 years of age","author":"Gasparini","year":"2008"},{"key":"10.1016\/j.vaccine.2009.05.003_bib36","series-title":"48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)\/Infectious Diseases Society of America (IDSA) 46th Annual meeting","article-title":"Safety and immunogenicity of MenACWY-CRM administered sequentially or concomitantly with Tdap and HPV vaccines","author":"Arguedas","year":"2008"},{"key":"10.1016\/j.vaccine.2009.05.003_bib37","series-title":"16th International Pathogenic Neisseria Conference (IPNC)","article-title":"MenACWY-CRM, a novel quadrivalent meningococcal conjugate vaccine, is well tolerated and immunogenic in infants through adolescents","author":"Dull","year":"2008"},{"key":"10.1016\/j.vaccine.2009.05.003_bib38","unstructured":"Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine\u2014United States, October 2005\u2013February 2006. MMWR 2006;55(13):364\u20136."},{"key":"10.1016\/j.vaccine.2009.05.003_bib39","series-title":"2nd Vaccine Congress","article-title":"Reactogenicity of MenACWY-CRM administered sequentially or concomitantly with Tdap and HPV vaccines","author":"Arguedas","year":"2008"},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.003_bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/01.inf.0000259996.95965.ef","article-title":"Use of meningococcal vaccines in the United States","volume":"26","author":"Bilukha","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2009.05.003_bib41","unstructured":"Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11\u201318 years with meningococcal conjugate vaccine. MMWR 2007;56(31):794\u20135."},{"key":"10.1016\/j.vaccine.2009.05.003_bib42","unstructured":"Centers for Disease Control and Prevention (CDC). National vaccination coverage among adolescents aged 13\u201317 year\u2014United States, 2006. MMWR 2007;56(34):885\u20138."},{"issue":"5","key":"10.1016\/j.vaccine.2009.05.003_bib43","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1542\/peds.2004-2514","article-title":"ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States","volume":"115","author":"Shepard","year":"2005","journal-title":"Pediatrics"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2009.05.003_bib44","doi-asserted-by":"crossref","first-page":"A97","DOI":"10.1016\/j.vaccine.2007.04.049","article-title":"The meningitis vaccine project","volume":"25","author":"LaForce","year":"2007","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09006689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T03:57:31Z","timestamp":1545191851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09006689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":44,"alternative-id":["S0264410X09006689"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.05.003","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}